Related Experiment Video

Updated: Jun 8, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies

Pei-Ming Yang1, Yuan-Ling Liu, Yi-Chu Lin

  • 1Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.

Cancer Research
|September 30, 2010
PubMed

Insights

Atorvastatin, a cholesterol-lowering statin, inhibits liver and colon cancer growth by inducing apoptosis and autophagy. Combining atorvastatin with autophagy inhibitors may improve digestive cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Statins, including atorvastatin, demonstrate anticancer properties, but their mechanisms are not fully understood.
  • Hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) are significant health concerns with ongoing research into novel therapeutic strategies.
  • Autophagy and apoptosis are critical cellular processes implicated in cancer development and treatment response.

Purpose of the Study:

  • To elucidate the mechanisms by which atorvastatin inhibits hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) cell growth.
  • To investigate the role of AMP-activated protein kinase (AMPK) and autophagy in atorvastatin's anticancer effects.
  • To explore the potential of combining atorvastatin with autophagy inhibitors for treating digestive malignancies.

Main Methods:

  • In vitro studies using HCC and CRC cell lines treated with atorvastatin.
  • Investigation of apoptosis and autophagy induction by atorvastatin.
  • Assessment of AMPK activation, p21 expression, and endoplasmic reticulum (ER) stress response.
  • Inhibition of autophagy using small interfering RNA (siRNA) or bafilomycin A1.
  • Correlation analysis of AMPK activity and autophagy markers in HCC and CRC patient samples.

Main Results:

  • Atorvastatin inhibited HCC and CRC cell growth by inducing apoptosis and autophagy.
  • Atorvastatin-induced autophagy was mediated by AMPK activation, which in turn induced p21 expression and ER stress.
  • AMPK activation and p21 expression were positively correlated with the autophagy marker beclin-1 in patient samples.
  • Inhibition of autophagy enhanced atorvastatin-induced cytotoxicity and apoptosis.
  • Autophagy appears to promote cancer cell survival under atorvastatin treatment.

Conclusions:

  • Atorvastatin activates AMPK, leading to p21 expression and ER stress, which induces autophagy.
  • Autophagy induced by atorvastatin promotes cancer cell survival, suggesting it as a pro-survival mechanism.
  • Combining atorvastatin with autophagy inhibitors like bafilomycin A1 presents a promising strategy for enhancing the treatment of digestive cancers.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...